Arcutis Launches Zoryve For Psoriasis As A New Topical In A Growing Category

Zoryve joins Dermavant's Vtama as a new topical drug with a broad label for plaque psoriasis and offers some points of differentiation, including price.

set sail
Arcutis has set sail on its first commercial launch • Source: Shutterstock

Arcutis Biotherapeutics, Inc. is launching its first commercial drug, Zoryve (roflumilast), a topical cream approved by the US Food and Drug Administration on 29 July for plaque psoriasis, joining a newly competitive category for non-steroidal topical drugs.

The approval of Zoryve follows closely on the heels of the launch of Dermavant Sciences Inc.'s Vtama (tapinarof), another...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip